hCBE 11

Drug Profile

hCBE 11

Alternative Names: Anti-lymphotoxin-beta-receptor-monoclonal-antibody; CBE-11-monoclonal-antibody; hCBE-11; Monoclonal-antibody-CBE-11

Latest Information Update: 13 Jun 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biogen Idec
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 25 Apr 2013 Discontinued - Phase-I for Solid tumours in USA (unspecified route)
  • 01 Jan 2005 Phase-I clinical trials in Solid tumours in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top